A recent randomized clinical trial from Johns Hopkins University highlights the emerging potential of psilocybin-assisted therapy as a novel approach to smoking cessation. In the study, 82 adult smokers—most of whom had previously struggled to quit—were assigned either a standard nicotine patch regimen or a single, supervised high dose of psilocybin, with both groups receiving 13 weeks of cognitive behavioral therapy (CBT).

A new VA-led study highlights the potential of GLP-1 receptor agonists—commonly used for diabetes and weight loss, including semaglutide (Ozempic)—as a novel approach to addressing substance use disorders (SUDs) among veterans. Drawing on data from more than 600,000 Veterans Affairs patients, researchers found that individuals prescribed GLP-1 medications had significantly lower risks of developing addiction across multiple substances, including alcohol, opioids, cannabis, cocaine, and nicotine.

San Francisco Mayor Daniel Lurie’s proposed “RESET” Center represents a shift in the city’s response to visible drug use and homelessness, but critics argue it risks repeating past failures under a new label. The facility would allow police to detain individuals arrested for public intoxication for up to 23 hours in a sobering setting, positioned as an alternative to jail and a pathway to treatment.

This article from Kwalu examines how dining models in senior living communities are evolving, with a growing emphasis on “bistro culture” to meet changing resident expectations. Rather than relying solely on traditional, scheduled dining in formal dining rooms, many communities are introducing more casual, café- and bistro-style spaces that offer greater flexibility and a more contemporary, hospitality-driven experience.

By Marlana Dant and Krystal Scharon
Featuring insights from Kent Lewis, Chief Evangelist of Gravitate Design

Published: March 19, 2026

Arrhythmia detection and monitoring are evolving rapidly, reshaping how cardiac electrophysiology (EP) teams identify, track, and manage rhythm disorders across the care continuum. Advances in artificial intelligence (AI), wearable and implantable technologies, and remote data integration are expanding diagnostic reach beyond the traditional EP lab—while introducing new workflow, data, and interpretation challenges for clinicians and device specialists.

Wearable technologies have rapidly evolved from consumer wellness tools into clinically relevant instruments for arrhythmia detection, particularly atrial fibrillation (AF). For cardiologists and electrophysiology (EP) teams, modern wearables now offer scalable options for screening, continuous rhythm monitoring, and earlier diagnosis across diverse patient populations.

In atrial fibrillation (AF), common modifiable conditions contribute to atrial remodeling and create a substrate for recurrent arrhythmia. Recent literature and guideline-aligned care pathways increasingly emphasize lifestyle and comorbidity management alongside rate/rhythm control.¹ This article highlights key modifiable risk factors and practical tools—targeting obesity, hypertension, sleep apnea, physical inactivity, diabetes, alcohol use, and tobacco exposure—to improve outcomes in AF.

What does “prevention” mean in contemporary AF management?
Atrial fibrillation (AF) prevention includes primary prevention (reducing incident AF through upstream risk factor modification) and secondary prevention (slowing AF progression, reducing recurrence and burden, and preventing AF-related adverse outcomes). Current US and European guidelines characterize AF as a staged, progressive disease, supporting early, longitudinal intervention.¹,²